Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Albany Molecular Research Inc. (AMRI) and BioPontis Alliance LLC Enter Preferred Provider Agreement to Identify New Drug Opportunities

Albany Molecular Research Inc., an Albany based global contract services and manufacturing organization, announced today that it will work with BioPontis Alliance, LLC in a preferred provider agreement to support BioPontis’ mission to bridge the gap between early stage research and technologies that come out of academia and other research outlets. AMRI will provide its expertise in small molecule discovery, development, and manufacturing. The partnership is expected to help find promising early stage product opportunities and create a preferred network of leading research companies to help develop new drugs to attract pharmaceutical company licensing partners.

BioPontis has formed research alliances with a consortium of leading universities and research institutions as it searches for new science that can be translated into treatments for cancer, neurology, inflammation and infectious diseases. The partnerships for identifying new technology include New York University, Columbia University, Memorial Sloan-Kettering Cancer Center, University of Pennsylvania, University of North Carolina, University of Virginia, University of Kansas, Oregon Health and Sciences University, Thomas Jefferson University and the University of Florida. BioPontis has also established preferred partnerships with pharmaceutical companies such as Janssen Biotech, Pfizer and Merck.

“Building on the recently announced collaborations with the National Institutes of Health and others, the relationship with BioPontis Alliance is another example of AMRI’s leading ability to contribute significant value in the discovery and development of the medicines of the future. Given the outreach by a number of pharmaceutical companies to the outside for innovative new approaches to treating disease, the BioPontis Alliance may fill an important need for the industry in identifying new therapeutic agents and approaches to treating unmet medical needs,” said Thomas E. D’Ambra, Ph.D, Chairman, President and CEO, AMRI in a press statement.

Over the past twenty years, AMRI has worked in the US, Europe and Asia to provide customers with fully integrated drug discovery, development and manufacturing services. It utilizes a range of technologies and services to support the growth of both new and existing drug products. AMRI has also used its drug-discovery expertise for internal drug discovery programs.

“For many reasons, and after significant due diligence, AMRI was the obvious partner of choice. We look forward to working with AMRI and all of our partners in helping to advance some of the new medicines for the future,” said Richard A. Basile, CEO and Principal, BioPontis Alliance LLC in a press release.

Please visit for more information on this preferred partnership.

Let us hear your thoughts below:

This entry was posted in Small Cap News. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *